LAVA Therapeutics N.V.

NasdaqGS:LVTX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Netherlands

Market Cap

USD 35.25 M

Share Price

USD 1.34

Avg Daily Volume

50,944

Change (1 day)

3.08%

Change (1 year)

Change (YTD)

45.65%

LAVA Therapeutics N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 4.99 M

LAVA Therapeutics N.V. Revenue is USD 4.99 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -60.20% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

LAVA Therapeutics N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 12.54 M, a -36.01% change year over year.
LAVA Therapeutics N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 19.59 M, a 272.28% change year over year.
LAVA Therapeutics N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 5.26 M, a 19.64% change year over year.
LAVA Therapeutics N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 4.40 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqGS: LVTX

LAVA Therapeutics N.V.

CEO	Mr. Stephen Allen Hurly M.B.A., M.Sc.
IPO Date	March 26, 2021
Location	Netherlands
Headquarters	Yalelaan 60
Employees	34
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.